Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 600 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $30.38, for a total value of $18,228.00. Following the transaction, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at approximately $22,592,846.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) traded down $0.75 on Friday, hitting $27.50. The stock had a trading volume of 655,000 shares, compared to its average volume of 1,469,842. The company has a market cap of $894.93, a P/E ratio of -7.93 and a beta of 1.27. Atara Biotherapeutics Inc has a 12-month low of $11.80 and a 12-month high of $30.90.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). sell-side analysts forecast that Atara Biotherapeutics Inc will post -4 earnings per share for the current fiscal year.
A number of research firms have weighed in on ATRA. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a report on Wednesday, January 3rd. Canaccord Genuity reiterated a “positive” rating and set a $70.00 price target (up previously from $47.00) on shares of Atara Biotherapeutics in a research report on Friday. Goldman Sachs Group reiterated a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a research report on Friday, October 6th. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Finally, ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $30.60.
Several institutional investors and hedge funds have recently modified their holdings of ATRA. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics during the 3rd quarter valued at about $142,000. Voya Investment Management LLC lifted its position in Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Atara Biotherapeutics in the 3rd quarter worth approximately $170,000. The Manufacturers Life Insurance Company lifted its position in Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after buying an additional 610 shares during the last quarter. Hedge funds and other institutional investors own 69.67% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/19/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-600-shares-of-stock.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.